| 6J1L: reference: Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORgamma Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer., Zhang Y, Wu X, Xue X, Li C, Wang J, Wang R, Zhang C, Wang C, Shi Y, Zou L, Li Q, Huang Z, Hao X, Loomes K, Wu D, Chen HW, Xu J, Xu Y, J Med Chem. 2019 Apr 22. doi: 10.1021/acs.jmedchem.9b00327. PMID: 30964293 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).